CN103301372B - Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence - Google Patents
Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence Download PDFInfo
- Publication number
- CN103301372B CN103301372B CN201310269332.5A CN201310269332A CN103301372B CN 103301372 B CN103301372 B CN 103301372B CN 201310269332 A CN201310269332 A CN 201310269332A CN 103301372 B CN103301372 B CN 103301372B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- prostate
- brown
- parched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of an umbilicus dressing agent for treating post-operation prostate stress urinary incontinence, which aims at solving the problem of treating post-operation prostate stress urinary incontinence. The preparation method is characterized by comprising the steps of: (1) carrying out decompression distillation on cortex erythrinae, fructus aurantii immaturus and radix ephedrae crude powder to extract volatile oil; (2) carrying out decompression decoction on tetrapanaxpapyrifer to obtain filtrate; (3) decocting smallflower bracketplant herb, rhizome of Japanese Galangal, largeflower jasmine flower, coking malt, scorch-fried medicated leaven, kamuning, peach gum, irkutsk anemone rhizome and decoction dregs obtained from the step (1) with water to obtain filtrate for later use; (4) combining the filtrates of the steps (2) and (3), carrying out concentration at reduced pressure to dry extract, and grinding to obtain dry extract powder; and (5) spraying the volatile oil obtained from the step (1) into the dry extract powder obtained from the step (4), evenly mixing, sieving through a 100-mesh sieve, and subpackaging. Proved by clinical experiments, the drug for treating post-operation prostate stress urinary incontinence has the characteristics of good curative effect and higher safety, thus being worth of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of treat prostate after stress incontinence apply the preparation method of umbilicus agent.
Background technology
Urinary incontinence is the complication that male prostate Post operation and urinary tract traumatic patient often occur.Such patient causes dysuria when urinating due to urethral stricture; Can not close completely due to urethra again when urine storage and cause urine independently not flow out from intravesical.This situation is regardless of time all can be occurred with occasion, thus often makes patient suffering can't bear.According to statistics, the probability of Benign Prostatic Hypertrophy Post operation generation urinary incontinence is 0.5% ~ 2.6%, and the probability of patients with prostate cancer Post operation generation urinary incontinence is 15% ~ 30%.At present, the few and unsatisfactory curative effect of the Therapeutic Method of this disease.All the time, the postoperative urinary incontinence of male is considered to " global problem " in Urological Field.
Clinically, after Chinese traditional treatment prostate, stress incontinence thinks that this disease is deficiency syndrome more, and the setting about for the treatment of is a little to tonify Qi of the kidney, conventional representative prescription as large complement decoct, Gu Yin decocts.But inventor's clinical research finds that blood supply minimizing and urethral mucosa there occurs functional in operation, and then there occurs fibrosis and even harden, define " freezing urethra ".Mucous membrane of urethra atrophy, gauffer reduces, thus urethra is followed the string, and suitable closedown swaging can not be provided to become urinary incontinence.Also namely this disease also has mucous membrane of urethra solid pathological product to occur on deficiency syndrome basis, so should fully take into account mucous membrane of urethra to lose foster atrophy, these key pathological links of connective tissue arrangement disorder fibrosis.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and after the little treatment prostate of side effect, stress incontinence applies umbilicus agent.
The technical scheme that the present invention solves its technical problem is: after one treats prostate, stress incontinence applies umbilicus agent, it is characterized in that being prepared from by the crude drug of following weight proportion: Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 ~ 12 parts, Flos jasmini 3 ~ 10 parts, Fructus Aurantii Immaturus 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Folium Et Cacumen Murrayae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Rhizoma Anemones Altaicae 10 ~ 25 parts.
Chinese medicine of the present invention can be prepared from by following method:
(1) by Cortex erythrinae, Fructus Aurantii Immaturus, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
The pressure of the distilling under reduced pressure in above-mentioned steps (1) is 0.1Mpa.
The pressure that decompression in above-mentioned steps (2) decocts is 0.4Mpa.
The pressure of the concentrating under reduced pressure in above-mentioned steps (4) is 0.4Mpa.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, flat.Return liver, kidney channel.Merit can wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.Merit can heat-clearing and toxic substances removing; Dissipating blood stasis stops blooding.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.Merit can tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; Wind syndrome of head is had a headache; Weak breath consumption of essence; Early whitening of beard and hair.
Alpinia japonica (Thunb.) Miq., is Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are pungent, warm.Return lung, spleen, Liver Channel.Merit can dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Flos jasmini is Oleaceae plants Flos jasmini Jasminu, the dry flower of grandiflorum L..Property mildly bitter flavor; Property is put down.Return Liver Channel.Merit can soothing liver-QI for relieving depression, promoting the circulation of QI to relieve pain.
Fructus Aurantii Immaturus is the dry young fruit of rutaceae Citrus aurantium Linn. Citrus aurantium L. and variety or Fructus Citri sinensis Citrus sinensis Osbeck.Merit can dispelling the stagnated QI intestinal stasis relieving.Nature and flavor are bitter, pungent, sour, temperature.Return spleen, stomach warp.Merit can dispelling the stagnated QI removing food stagnancy, loose painful abdominal mass of reducing phlegm.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven of fermentation, fry to burnt brown according to frying method.Nature and flavor sweet, acrid, warm.Enter spleen, stomach warp.Merit can invigorating the spleen and regulating the stomach, helps digestion in adjusting.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, flat.GUIXIN, lung meridian.Merit can hidroschesis.
Folium Et Cacumen Murrayae is dried leaves and the band leaf twig of rutaceae Folium Et Cacumen Murrayae Murraya exotica L. and Murraya paniculata (L.) Jack. Murraya paniculata (L.) xJack.Pungent, micro-hardship, temperature.Promoting the circulation of QI to relieve pain, promoting blood circulation to remove blood stasis.
Gumshiraz is rosaceous plant Fructus Persicae Prunus persica (L.) Batsch, the resin that trunk flows out.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Rhizoma Anemones Altaicae, is Ranunculaceae thimbleweed anemone altaica Anemone altaica Mey., is used as medicine with root stock.Nature and flavor are pungent, temperature.Merit can causing resuscitation with aromatic drugs, reduces phlegm, calms the nerves.
Composition principle: after Chinese traditional treatment prostate, stress incontinence thinks that this disease is deficiency syndrome more, the setting about for the treatment of is a little to tonify Qi of the kidney, conventional representative prescription as large complement decoct, Gu Yin decocts.But inventor's clinical research finds that blood supply minimizing and urethral mucosa there occurs functional in operation, and then there occurs fibrosis and even harden, define " freezing urethra ".Mucous membrane of urethra atrophy, gauffer reduces, thus urethra is followed the string, and suitable closedown swaging can not be provided to become urinary incontinence.Also namely this disease also has mucous membrane of urethra solid pathological product to occur on deficiency syndrome basis, so should fully take into account mucous membrane of urethra to lose foster atrophy, these key pathological links of connective tissue arrangement disorder fibrosis.
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using medicine of tonifying Qi of the kidney in a large number: get Cortex erythrinae in side, go back bobbin for monarch, the Cortex erythrinae dosage recorded in " China is herbal " is: " for oral administration: to decoct soup, 6-12g "; Inventor to test in proof heavy dose of Cortex erythrinae (10 ~ 30g) and can recover by specific promotion urethral wall mucosa, and goes back bobbin and have similar smooth muscle dual regulation, unbalance for sphincter vesicae shrinkage expansion;
2, characteristic of the present invention is also balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbid ", but postoperative patient resembling often with deficiency of YIN-blood, and now use Cortex erythrinae, then have and fear its hematozemia and cause yin asthenia generating intrinsic heat to occur; Therefore add Herba Chlorophyti Laxi and go back bobbin, also bobbin merit can train base by tonify deficiency, and can prevent Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize on the one hand it coldly to prevent heated, its merit can dissipating blood stasis hemostasis on the other hand, has out entire merit in blood system, prevent Cortex erythrinae to wander away dynamic blood, also can not affect Cortex erythrinae works orderly effect simultaneously; 2. in we, the use of Rhizoma Anemones Altaicae is: a causing resuscitation with aromatic drugs and benefaction, two Yin Yang balancings, and to balance the bitter cold of our invasion by pathogenic cold medicine of a cold nature thing, inventor's clinical research finds that Rhizoma Anemones Altaicae is activated yang and do not consume the moon in addition, is suitable for postoperative patient and uses; In prescription of the present invention, the application characteristic of Rhizoma Anemones Altaicae is: measure larger (consumption in " Chinese Pharmacopoeia " is 1.5-6g), so too disperse for preventing, gets again Radix Ephedrae convergence assistant system;
3, supplementary drug thing is fewer but better: get Alpinia japonica (Thunb.) Miq. assistant in side and help Herba Chlorophyti Laxi, it act as giving treatment in accordance with the tendency of pathological change, regulating air activity; Fructus Aurantii Immaturus and Herba Chlorophyti Laxi are arranged in pairs or groups removing toxic substances, eliminating stagnation effect, for these pathological products of connective tissue arrangement disorder fibrosis; Inventor's clinical research shows: Flos jasmini can alleviate bladder irritation effectively; Gumshiraz is invigorated blood circulation, and contributes to drag residence in local, penetration enhancement;
4, inventor's clinical research finds, solid protection gastric qi contributes to the process control of stress incontinence drug disease and recovery after prostate, so select Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown) spleen benefiting and stimulating the appetite;
5, Folium Et Cacumen Murrayae is supplementary drug thing, and the present inventor's experimental study finds, gets low dose of Folium Et Cacumen Murrayae decocting liquid and can improve in vitro mucous membrane of urethra cytoactive;
6, the homogeneous medicine multiple-effect of institute's thing of getting it filled in side, contributes to reducing medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, and each raw material dosage is for all to have good curative effect in following weight parts scope;
8, the fruit that bobbin is orchid Rhizoma Gastrodiae is gone back, compared with Rhizoma Gastrodiae, going back the Esterified Enzyme isozyme (esterase isoenzyme) that bobbin contains, may be that it plays the key of pharmacological action, and inventor's experiment draws, it is higher that decompression goes back bobbin Esterified Enzyme isozyme content after decocting.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Alpinia japonica (Thunb.) Miq. 10g, Flos jasmini 6g, Fructus Aurantii Immaturus 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Folium Et Cacumen Murrayae 2g, gumshiraz 6g, Rhizoma Anemones Altaicae 20g.
The preparation method of embodiment 1 is: by Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Aurantii Immaturus, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Folium Et Cacumen Murrayae, gumshiraz, the decoction of Rhizoma Anemones Altaicae mixing and water adding, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges umbilical part soak, once a day.
Embodiment 2, crude drug weight proportion: Cortex erythrinae 10 parts, Herba Chlorophyti Laxi 6 parts, go back 3 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 parts, Flos jasmini 3 parts, Fructus Aurantii Immaturus 6 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Massa Medicata Fermentata (parched to brown) 6 parts, Radix Ephedrae 6 parts, Folium Et Cacumen Murrayae 1 part, gumshiraz 3 parts, Rhizoma Anemones Altaicae 10 parts.
Embodiment 3, crude drug weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Flos jasmini 6 parts, Fructus Aurantii Immaturus 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Folium Et Cacumen Murrayae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts.
Embodiment 4, crude drug weight proportion: Cortex erythrinae 30 parts, Herba Chlorophyti Laxi 12 parts, go back 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 12 parts, Flos jasmini 10 parts, Fructus Aurantii Immaturus 12 parts, Fructus Hordei Germinatus (parched to brown) 12 parts, Massa Medicata Fermentata (parched to brown) 12 parts, Radix Ephedrae 12 parts, Folium Et Cacumen Murrayae 5 parts, gumshiraz 10 parts, Rhizoma Anemones Altaicae 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) by Cortex erythrinae, Fructus Aurantii Immaturus, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
In prioritization scheme, the pressure of the distilling under reduced pressure in described step (1) is 0.1Mpa; The pressure that decompression in described step (2) decocts is 0.4Mpa; The pressure of the concentrating under reduced pressure in described step (4) is 0.4Mpa.
The efficient combination of said medicine, coordinates mutually, effectively reach the object of stress incontinence medicine after treatment prostate, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case selection: in December, 2011 ~ 2013 to be diagnosed as women with stress urinary incontinence 48 example after prostate year June, and eliminating excreting excrement system infects and kidney disease, previously without operation on pelvis history and neuromuscular pathological changes.
1.1.2 the diagnostic criteria of stress incontinence 1. firmly time while changing position (cough, laugh, remove weight) there is autonomous leakage of urine; 2. Pad test: namely allow patient bring diaper, jog after great quantity of water drinking, stair climbing, lift the activities such as weight, checks after 30min, 60min that diaper finds that leakage of urine and moist person are for positive.Any one in above-mentioned two is positive, and diagnosable is stress incontinence.
1.1.3 divide into groups: be divided into soak group 24 example and deposited umbilicus group 24 example.Compare in age, the state of an illness, the course of disease before two groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method: soak group with gained decoct umbilical part soak in the embodiment of the present invention 1,3 times/d.Applying umbilicus group adjusts rear umbilical part to dress with gained powder vinegar in the embodiment of the present invention 3,1 time/d.February is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after medication, and carry out general questionnaire survey scoring, evaluate its situation of urinating.
1.2.3 criterion of therapeutical effect: be recorded as Outcome measure index with 24h Pad test card of urinating.Curing: incontinence disappears, or Pad test <2g, is effectively that urinary incontinence number of times or Pad test reduce degree >50%; Invalid is that urinary incontinence number of times or Pad test reduce degree <50%.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.ICIQ-SF scoring adopts nonparametric statistics.Measurement data t checks, enumeration data χ
2inspection.
2 results.
2.1 treatment front and back urinary incontinence number of times every day compare: before treatment, soak group is 3.9 ± 1.4, applying umbilicus group is 4.1 ± 1.6, and after treatment, soak group is 1.2 ± 0.6, and applying umbilicus group is 1.3 ± 0.5, compare before and after treatment, two groups have notable difference (P<0.05).
2.2 clinical efficacies: medication is after 8 weeks, and the cure rate of soak group, effective percentage, inefficiency are respectively 33.33%, 41.67%, 25.00%, total effective rate is 75.00%.The cure rate of deposited umbilicus group, effective percentage, inefficiency are respectively 33.33%, 37.50%, 29.17%, and total effective rate is 66.67%.
2.3 adverse reaction rates: two groups of patients all do not occur obvious adverse reaction.
3. conclusion.
This result of study show, soak group of the present invention and deposited umbilicus group treatment prostate after stress incontinence total effective rate be 75.00% and 66.67%.Have the advantage that untoward reaction is comparatively light, safety is higher.
Claims (4)
1. one kind treat prostate after stress incontinence apply the preparation method of umbilicus agent, it is characterized in that, crude drug is: Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 ~ 12 parts, Flos jasmini 3 ~ 10 parts, Fructus Aurantii Immaturus 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Folium Et Cacumen Murrayae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Rhizoma Anemones Altaicae 10 ~ 25 parts; Its preparation method is made up of following steps:
(1) by Cortex erythrinae, Fructus Aurantii Immaturus, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Et Cacumen Murrayae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms;
During use, vinegar adjusts rear umbilical part to dress.
2. according to claim 1 a kind of treat prostate after stress incontinence apply the preparation method of umbilicus agent, it is characterized in that: the pressure of the distilling under reduced pressure in described step (1) is 0.1MPa.
3. according to claim 1 a kind of treat prostate after stress incontinence apply the preparation method of umbilicus agent, it is characterized in that: the pressure that the decompression in described step (2) decocts is 0.4MPa.
4. according to claim 1 a kind of treat prostate after stress incontinence apply the preparation method of umbilicus agent, it is characterized in that: the pressure of the concentrating under reduced pressure in described step (4) is 0.4MPa.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269332.5A CN103301372B (en) | 2013-07-01 | 2013-07-01 | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence |
| CN201510104982.3A CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269332.5A CN103301372B (en) | 2013-07-01 | 2013-07-01 | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510104982.3A Division CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103301372A CN103301372A (en) | 2013-09-18 |
| CN103301372B true CN103301372B (en) | 2015-02-11 |
Family
ID=49127378
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310269332.5A Expired - Fee Related CN103301372B (en) | 2013-07-01 | 2013-07-01 | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence |
| CN201510104982.3A Pending CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510104982.3A Pending CN104758765A (en) | 2013-07-01 | 2013-07-01 | Umbilical region wet-applying agent for treating prostatic postoperation stress incontinence |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103301372B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491133A (en) * | 2014-12-14 | 2015-04-08 | 刘海燕 | Traditional Chinese medicine foot bathing agent for treating urinary bladder spasm after prostate surgery and nursing method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988702A (en) * | 2012-12-16 | 2013-03-27 | 孟伟伟 | Navel dressing and nursing agent used for treatment after prostatectomy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279007B (en) * | 2008-05-17 | 2010-10-27 | 刘淑霞 | Chinese medicine for curing aconuresis |
| CN101804169A (en) * | 2010-05-28 | 2010-08-18 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating urinary incontinence and preparation method thereof |
| CN102614487A (en) * | 2012-04-19 | 2012-08-01 | 田书庭 | Plaster for treatment of prostate and uracratia |
-
2013
- 2013-07-01 CN CN201310269332.5A patent/CN103301372B/en not_active Expired - Fee Related
- 2013-07-01 CN CN201510104982.3A patent/CN104758765A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988702A (en) * | 2012-12-16 | 2013-03-27 | 孟伟伟 | Navel dressing and nursing agent used for treatment after prostatectomy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104758765A (en) | 2015-07-08 |
| CN103301372A (en) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102166278B (en) | Chinese medicinal composition for treating pediatric rheumatoid arthritis and preparation method thereof | |
| CN102366623B (en) | Preparation method of traditional Chinese medicine for treating qi deficiency-type bedsore | |
| CN103877247A (en) | Medicine for treating bedsore and preparation method thereof | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| CN103285300B (en) | Medicinal composition for treating stress incontinence | |
| CN103301372B (en) | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN105412621A (en) | Method for preparing pharmaceutical composition for treating hemorrhoids | |
| CN105343578A (en) | Medicine composition for treating haemorrhoids | |
| CN106110218B (en) | A kind of anti-cancer pain pain relieving plaster and preparation method thereof | |
| CN104623532A (en) | Traditional Chinese medicine composition for treating glioma and preparation method thereof | |
| CN103285301B (en) | Method for preparing umbilicus dressing agent for treating stress incontinence | |
| CN104840773A (en) | Traditional Chinese medicine composition for treating vertebral artery type cervical spondylopathy and method for preparing same | |
| CN103301371B (en) | Preparation method of umbilicus dressing agent for treating primary enuresis | |
| CN103301375B (en) | Preparation method of umbilical sticking agent for treating nocturia of children | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103301378B (en) | Pharmaceutical composition for treating nocturia of children | |
| CN107617081A (en) | The Chinese medicine composition and its preparation and preparation method of a kind of hair growth | |
| CN105998519A (en) | Oral medicine for treating frequent micturition due to pelvic inflammatory disease | |
| CN106806680A (en) | Raw white side's prepared slices of Chinese crude drugs combination preparation, preparation method and assembly packaging | |
| CN106166206A (en) | A kind of gynecological inflammation causes the rehabilitation medicine preparation method of frequent micturition | |
| CN105412392A (en) | Traditional Chinese medicinal composition for treating hemorrhoids and preparation method of traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150211 Termination date: 20150701 |
|
| EXPY | Termination of patent right or utility model |